SLAMF3/CD229 was expressed in 20% of BL cases, 52% non-GC-DLBCL, 60% FL, 66% GC-DLBCL, 70% CLL, 70% MCL, 82% nodal MZL, 86% mucosa-associated lymphoid tissue (MALT) lymphoma, and 87% splenic MZL. Here, LY9 is linked to MALT lymphoma.